Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold
- PMID: 30705864
- PMCID: PMC6328698
- DOI: 10.21037/tlcr.2018.08.12
Elderly patients with stage III NSCLC survive longer when chemotherapy is added to radiotherapy-fortune favours the bold
Conflict of interest statement
Conflicts of Interest: Paul Mitchell declares Advisory Boards—AstraZeneca, Roche, Boehringer-Ingelheim, BMS, MSD, Celgene; Honoraria—Roche, Merck KGa; Travel Grants (conferences)—Roche, BMS, AstraZeneca. Dr. Surein Arulananda has no conflicts of interest to declare.
Comment on
-
The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer.J Thorac Oncol. 2018 Mar;13(3):426-435. doi: 10.1016/j.jtho.2017.11.135. Epub 2018 Jan 8. J Thorac Oncol. 2018. PMID: 29326090 Free PMC article.
References
-
- National Cancer Institute: SEER stat fact sheets: Lung and bronchus cancer. Available online: https://seer.cancer.gov/statfacts/html/lungb.html. Accessed 28 July 2018.
Publication types
LinkOut - more resources
Full Text Sources